Io Therapeutics, Inc.
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
1
Ending by 2030
Apr 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 16, 2026The maintenance fee for Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds in Combination with Immune Modulators for Cancer Immunotherapy (US 11,648,223) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
- 3 fees due Jan 4 to 30, 2027 · next Jan 4
- 1 fee due Feb 28, 2027The maintenance fee for Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy (US 11,737,996) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 3 fees due Apr 10 to 24, 2027 · next Apr 10
- 3 fees due May 12 to 26, 2027 · next May 12
- 1 fee due Jun 30, 2027The maintenance fee for Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy (US 10,517,843) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 2 fees due Jul 14, 2027
- 3 fees due Sep 5 to 17, 2027 · next Sep 5
- 1 fee due Oct 12, 2027The maintenance fee for Treatment of Cancer with Specific RXR Agonists (US 9,308,186) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Synthesis of tetrahydronaphthalenols and uses thereof (US 11,976,021) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 4 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,308,186 | Treatment of Cancer with Specific RXR Agonists In force · Medium confidence | In force | Medium confidence | |
| US 10,695,307 | Autoimmune disorder treatment using RXR agonists In force · From the USPTO record | In force | From the USPTO record | |
| US 10,945,976 | Autoimmune disorder treatment using RXR agonists In force · From the USPTO record | In force | From the USPTO record | |
| US 11,576,881 | Autoimmune Disorder Treatment Using RXR Agonists In force · Low confidence | In force | Low confidence | |
| US 9,877,941 | Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones In force · High confidence | In force | High confidence | |
| US 10,278,932 | Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones In force · High confidence | In force | High confidence | |
| US 10,485,778 | Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones In force · Medium confidence | In force | Medium confidence | |
| US 10,588,881 | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones In force · From the USPTO record | In force | From the USPTO record | |
| US 10,695,312 | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones In force · From the USPTO record | In force | From the USPTO record | |
| US 10,702,489 | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 52: 15 patents in force now held by others · 9 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 11 abandoned · 14 no status recorded